Laval, Quebec drugmaker Milan Panić founded in 1959 as ICN Pharmaceuticals, later called Valeant; sells branded, generic and over-the-counter medicines in more than 90 countries and is listed on the TSX as BHC.
Market cap $3.1B on 21 Nov 2026
| Pershing Square | William Ackman | 11 | 2014–2017 |
| Giverny Capital | Francois Rochon | 6 | 2011–2016 |
| Chou Associates Management | 2 | 2026–2026 | |
| Shelton Capital Management | 2 | 2025–2025 | |
| Third Point | Daniel Loeb | 1 | 2026–2026 |
| Third Point Q3 2026 Investor Letter | Third Point returned -6.8% in Q3 2026 as AI and memory stocks sold off; it cut exposure and explains Atom Computing, APi Group, an Nscale convertible loan, Bausch Health and its credit books. | Third Point | Daniel Loeb | Q3 2026 |
| Shelton Tactical Credit Fund Institutional Class Annual TSR 2025 | Shelton reports that the Tactical Credit Fund's Institutional Class returned 8.55% in 2025 against 7.30% for the Bloomberg US Aggregate Bond Index, from shorter duration, slightly more credit-sensitive positioning, trading around volatility and event-driven gains in bonds of PetSmart, Calpine, Rivian and others. | Shelton Capital Management | Shelton Capital Management | 2025 |
| Shelton Tactical Credit Fund Investor Class Annual TSR 2025 | Shelton reports that the Tactical Credit Fund's Investor Class returned 8.21% in 2025 against 7.30% for the Bloomberg US Aggregate Bond Index, from shorter duration, slightly more credit-sensitive positioning, trading around volatility and event-driven gains in bonds of PetSmart, Calpine, Rivian and others. | Shelton Capital Management | Shelton Capital Management | 2025 |
| Chou Bond Fund 2026 Interim Management Report of Fund Performance | Chou Associates Management reports that Chou Bond Fund rose 4.1% (Series A) in Canadian dollars in the first half of 2026, against 5.5% for the Barclays Capital U.S. Corporate High Yield Index, while holding an average of 64.4% of net assets in cash, with EXCO Resources shares contributing most and Hertz and Bausch Health bonds detracting. | Chou Associates Management | Chou Associates Management | 2026 |
| Chou Bond Fund 2026 Interim Management Report of Fund Performance (French) | Chou Associates Management reports that Chou Bond Fund rose 4.1% (Series A) in Canadian dollars in the first half of 2026, against 5.5% for the Barclays Capital U.S. Corporate High Yield Index, while holding an average of 64.4% of net assets in cash, with EXCO Resources shares contributing most and Hertz and Bausch Health bonds detracting. | Chou Associates Management | Chou Associates Management | 2026 |
| Letter to Shareholders, 2017 Annual Report (letter extract) | Bill Ackman reviews Pershing Square's 20.5% annual return from 2004 to mid-2015 and the three years of underperformance that followed. | Pershing Square | William Ackman | 2017 |
| Letter to Shareholders in the 2017 Semiannual Financial Statements | Pershing Square Holdings' 2017 interim report covers the chairman's statement and investment manager's report for the first half. | Pershing Square | William Ackman | 2017 |
| Letter to Shareholders, 2016 Annual Report (letter extract) | Bill Ackman calls 2016 a year of progress despite losses: NAV rose 16.3% from its March low despite a 390 basis point drag from Valeant. | Pershing Square | William Ackman | 2016 |
| Letter to Shareholders in the 2016 Semiannual Financial Statements | Pershing Square calls the twelve months to mid-2016 its worst period since 2004, though performance had recently improved. | Pershing Square | William Ackman | 2016 |
| Pershing Square Holdings Q1 2016 Investor Letter | Pershing Square's Q1 2016 letter attributes performance by holding, with Air Products among the contributors. | Pershing Square | William Ackman | Q1 2016 |
| 2016 European Investor Meeting presentation (Herbalife) | Pershing Square's April 2016 European investor meeting presentation sets out its case against Herbalife. | Pershing Square | William Ackman | 2016 |
| Letter to Shareholders in the 2015 Annual Report | Bill Ackman returns to the 2015 annual letter to discuss events at Valeant in the two months after it was sent. | Pershing Square | William Ackman | 2015 |
| Letter to Shareholders, 2015 Annual Report (letter extract) | Bill Ackman's 2015 annual report letter extract discusses events at Valeant after the January 2016 annual letter. | Pershing Square | William Ackman | 2015 |
| Letter to Shareholders in the 2015 Semiannual Financial Statements | Pershing Square Holdings outperformed the S&P 500 in the first half of 2015, year to date and since inception. | Pershing Square | William Ackman | 2015 |
| Letter to Shareholders in the 2014 Annual Report | Bill Ackman's first annual letter to public PSH investors reviews Pershing Square's strategy as it developed over eleven years. | Pershing Square | William Ackman | 2014 |
| Letter to Shareholders, 2014 Annual Report (letter extract) | Bill Ackman's 2014 letter extract reviews Pershing Square's strategy over eleven years for new public PSH investors. | Pershing Square | William Ackman | 2014 |
| Giverny Capital Annual Letter to Partners 2016 | François Rochon reviews 2016 for Giverny's partners. | Giverny Capital | Francois Rochon | 2016 |
| Giverny Capital Annual Letter to Partners 2015 | François Rochon reviews 2015 for Giverny's partners. | Giverny Capital | Francois Rochon | 2015 |
| Giverny Capital Annual Letter to Partners 2014 | François Rochon reviews 2014 for Giverny's partners. | Giverny Capital | Francois Rochon | 2014 |
| Giverny Capital Annual Letter to Partners 2013 | François Rochon reports Giverny has compounded 15.5% a year since July 1993, against 8.3% for its benchmark. | Giverny Capital | Francois Rochon | 2013 |
| Giverny Capital Annual Letter to Partners 2012 | Giverny's portfolio returned 21.5% in 2012 against 12.5% for its benchmark. | Giverny Capital | Francois Rochon | 2012 |
| Giverny Capital Annual Letter to Partners 2011 | Giverny's portfolio returned 7.8% in 2011 against a 1.1% loss for its benchmark. | Giverny Capital | Francois Rochon | 2011 |
The top five winners for the quarter were Atom Computing Inc. (a legacy private position), Warner Bros Discovery Inc., Meta Platforms Inc., Indra Sistemas SA, and Bausch Health Cos Inc.Show in the letter ›
Third Point Q3 2026 Investor Letter · Third Point · page 1 · Q3 2026
On the long side, Bausch Health performed strongly on continued solid operating results and a favorable patent ruling.Show in the letter ›
Third Point Q3 2026 Investor Letter · Third Point · page 9 · Q3 2026
Au cours de la même période, les titres de créance de The Hertz Corporation, 12,625 %, échéant le 15 juillet 2029, et de Bausch Health Companies Inc., 14,000 %, échéant le 15 octobre 2030, sont ceux qui ont le moins contribué au rendement.Show at the source ↗
Chou Bond Fund 2026 Interim Management Report of Fund Performance (French) · Chou Associates Management · page 3 · 2026
The major underperformers in the period were the debt holdings of The Hertz Corporation, 12.625% due July 15, 2029 and Bausch Health Companies Inc., 14.000% due October 15, 2030.Show at the source ↗
Chou Bond Fund 2026 Interim Management Report of Fund Performance · Chou Associates Management · page 3 · 2026
In addition, the Fund realized event-driven gains in PetSmart, Sun Communities, Calpine, Acushnet, Digicel, Rivian, Guitar Center, Uniti Group, Bausch Health, Cinemark, and JBS Foods by mergers, acquisitions, refinancings, credit rating upgrades and other corporate events.Show at the source ↗
Shelton Tactical Credit Fund Investor Class Annual TSR 2025 · Shelton Capital Management · page 1 · 2025
In addition, the Fund realized event-driven gains in PetSmart, Sun Communities, Calpine, Acushnet, Digicel, Rivian, Guitar Center, Uniti Group, Bausch Health, Cinemark, and JBS Foods by mergers, acquisitions, refinancings, credit rating upgrades and other corporate events.Show at the source ↗
Shelton Tactical Credit Fund Institutional Class Annual TSR 2025 · Shelton Capital Management · page 1 · 2025
William Ackmandiscussed it in 11 letters
Francois Rochondiscussed it in 6 letters
Cindy Eckertnamed it in 1 interview“In 2015, Cindy sold the company to Valeant Pharmaceuticals for $1b cash.” — Sprout Pharmaceutical's $1 Billion little pink pill - Ep 186 (FemTech Focus, 2022)| Sprout Pharmaceutical's $1 Billion little pink pill - Ep 186 | Cindy Eckert | FemTech Focus | 2022-11-07 | 59 min | Cindy Eckert is a highly regarded entrepreneur, a strong advocate for female entrepreneurship, a pharmaceutical leader and one of the few women to have ever sold a company for a billion dollars. Over a distinguished 24-year career in healthcare, she started and sold two businesses for more than $1.5 billion. Having co-founded and sold Slate Pharmaceuticals, which redefined long lasting testosterone treatment for men, she launched Sprout Pharmaceuticals immediately thereafter. As Co-Founder & CEO of Sprout, the company broke through with the first ever FDA-approved drug for low sexual desire in women named Addyi — dubbed “female Viagra” by the media. In 2015, Cindy sold the company to Valeant Pharmaceuticals for $1b cash. Shortly after the sale, Valeant became the subject of media scrutiny for the rampant price inflation of their drugs and an SEC investigation related to accounting practices. Not one to sit idly by, Cindy negotiated to reacquire Addyi at no cost, in order to properly launch it into marketplace on her own terms. Today, Cindy is focused on mentoring, investing in, launching and building other women-led or focused businesses. In 2016, she opened the doors to The Pink Ceiling — a cross between a VC firm, a ‘pinkubator,’ and a consulting enterprise — where she is CEO. At The Pink Ceiling, she has personally invested $15m across 10 different health tech companies at various stages of development. |